Vilazodone Hydrochloride Tablet, Film Coated
Product Images NDC 69097-979

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Vilazodone Hydrochloride (NDC 69097-979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Vilazodone_structure (Vilazodone HCl Strctr)

Chemical structure of Vilazodone hydrochloride dihydrate showing the molecular arrangement with hydrochloride and water of crystallization components.*

FDA Label Image

Vilazodone_10mg (Vilazodone 10mg Label)

Vilazodone Hydrochloride Tablets 10 mg film-coated tablets label. The carton specifies 30 tablets per package and is manufactured for Cipla USA Inc. by ImvaGen Pharmaceuticals, Inc. It includes instructions for pharmacists to dispense the Medication Guide and storage conditions of 20° to 25°C (68° to 77°F). The label also features a barcode and standard Rx only markings.*

FDA Label Image

Vilazodone_20mg (Vilazodone 20mg Label)

Label for Vilazodone Hydrochloride Tablets 20 mg by Cipla USA Inc. The label includes the NDC 69097-981-02, states the product is Rx only, and a package count of 30 tablets. It specifies storage conditions and notes the product is manufactured by InvaGen Pharmaceuticals, a Cipla Ltd. subsidiary.*

FDA Label Image

Vilazodone_40mg (Vilazodone 40mg Label)

Vilazodone Hydrochloride Tablets 40 mg film-coated tablets label showing product name, strength, quantity of 30 tablets, and Cipla USA Inc. as manufacturer. The label includes storage instructions, dispensing guidance for pharmacists, and a barcode on the right side.*

FDA Label Image

Vilazodone_fig1 (Vilazodone Hydrochloride Figure 1)

A forest plot showing fold changes and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC due to ethanol, CYP3A4 inhibitors (ketoconazole), CYP3A4 inducers (carbamazepine), and proton pump inhibitors (pantoprazole). The x-axis represents change relative to reference, ranging from 0.5 to 2.0, with data points indicating increases or decreases in drug exposure.*

FDA Label Image

Vilazodone_fig2 (Vilazodone Hydrochloride Figure 2)

A pharmacokinetic chart showing fold changes and 90% confidence intervals in the activity of various CYP450 enzyme substrates and P-glycoprotein substrates relative to a reference. The chart includes substrates like nifedipine, caffeine, debrisoquine, flurbiprofen, mephenytoin, and digoxin, displaying their fold change values and confidence intervals on a scale from 0.5 to 2.0.*

FDA Label Image

Vilazodone_fig3 (Vilazodone Hydrochloride Figure 3)

A forest plot chart displaying fold change and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC. It compares population subgroups (>65 years, females) and impairment statuses (mild, moderate, severe renal and hepatic impairment) relative to a reference, showing changes in drug exposure for Vilazodone hydrochloride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.